Fairmount Funds Management LLC
Fairmount Funds Management LLC is a Philadelphia-based hedge fund established in 2020. The firm specializes in managing life sciences and healthcare-focused investment vehicles, catering primarily to institutional investors. As of March 2025, Fairmount manages approximately $3.2 billion in assets and employs over 30 professionals, nearly half of whom are investment staff. The firm is known for its concentrated, research-driven approach to growth and event-driven strategies within biotechnology and healthcare.
Investment Strategy
Fairmount Funds Management LLC employs a fundamental, research-driven investment approach, with a primary focus on life sciences and healthcare companies, especially those in the biotechnology sector. The firm seeks both public and private investment opportunities with a bias toward long-term value creation and company-specific catalysts. Fairmount favors a concentrated portfolio, aiming for deep understanding and engagement with a select group of high-conviction positions, often participating in company financings and taking active ownership roles where appropriate.
Latest 13F Filing Activity
Fairmount Funds Management LLC filed their most recent 13F report on Jun 30, 2025 disclosing 17 equity positions with a total 13F market value of $772M. The fund increased holdings in Jade Biosciences Inc., Kiniksa Pharmaceuticals Intl, Crescent Biopharma Inc. among other positions. Fairmount Funds Management LLC reduced exposure to Axsome Therapeutics Inc., Spyre Therapeutics Inc., Inhibikase Therapeutics Inc. among others.
Top Holdings
Equity Positions (17)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
A APGE | APOGEE THERAPEUTICS INC | 11.53% | $89.0M | 2,048,647 | $21.30 | $43.43 | +$12.4M |
A AXSM | AXSOME THERAPEUTICS INC | 11.02% | $85.1M | 815,176 | $50.70 | $104.39 | -$10.0M |
E ELVN | ENLIVEN THERAPEUTICS INC | 9.65% | $74.5M | 3,711,444 | $20.69 | $20.06 | +$11.4M |
S SRRK | SCHOLAR ROCK HLDG CORP | 8.37% | $64.6M | 1,824,031 | $41.30 | $35.42 | +$20.4M |
S SYRE | SPYRE THERAPEUTICS INC | 7.79% | $60.2M | 4,018,101 | $23.39 | $14.97 | -$4.7M |